Nymox Pharmaceutical

NYMXPhase 3

Nassau, BahamasFounded 1989nymox.com

Nymox Pharmaceutical is dedicated to addressing significant unmet medical needs in urology, particularly in the large and growing market for BPH treatments. The company's proprietary drug candidate, fexapotide triflutate, represents a novel, minimally invasive approach that has demonstrated long-term efficacy and a favorable safety profile in clinical studies. Despite facing regulatory and financial challenges, Nymox continues to pursue the development and potential commercialization of its lead asset. The company's strategic direction hinges on securing regulatory approval and partnerships to bring its innovative therapy to market.

Market Cap

$18.3M

Founded

1989

Employees

1-10

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary injectable oligopeptide (fexapotide triflutate) designed for targeted intraprostatic administration to induce localized apoptosis, aiming for long-term treatment effects from minimal injections.

Pipeline Snapshot

6 drugs in pipeline, 4 in Phase 3

Drug	Indication	Stage
NX-1207 + Placebo	Benign Prostatic Hyperplasia (BPH)	Phase 3
NX-1207	Benign Prostatic Hyperplasia	Phase 3
NX-1207 + Placebo	Benign Prostatic Hyperplasia	Phase 3
NX-1207	Benign Prostatic Hyperplasia	Phase 3
NX-1207 2.5 mg + NX-1207 15 mg	Prostate Cancer	Phase 2

Funding History

Total raised: $30M

PIPE$10MUndisclosedApr 15, 2021

PIPE$15MUndisclosedSep 15, 2015

Series A$5MUndisclosedJun 15, 2005

Opportunities

The primary opportunity is to address the large, underserved BPH market with a novel, durable, in-office injectable therapy that could sit between daily pills and surgery.

Successful approval and partnership could unlock significant value.

Risk Factors

Extreme financial risk with recurring 'going concern' warnings, high uncertainty around FDA regulatory pathway for its lead asset, lack of commercialization capabilities, and intense competition from both generic drugs and established minimally invasive procedures.

Competitive Landscape

Competes against generic oral BPH drugs (alpha-blockers, 5-ARIs) and rapidly growing Minimally Invasive Surgical Therapies (MIST) like UroLift and Rezūm. Differentiation hinges on fexapotide being a durable 'interventional drug' with long-term efficacy data from a few injections.